Cohort profile: French hospital database on HIV (FHDH-ANRS CO4)

International Journal of Epidemiology

Volumn 43, Issue 5, 2014, Pages 1425-1436

  Mary Krause, Murielle ^a,b   Grabar, Sophie ^a,b,c,d   Liévre, Laurence ^a,b   Abgrall, Sophie ^a,b,e   Billaud, Eric ^f   Boué, François ^c   Boyer, Laurence ^g   Cabié, André ^h   Cotte, Laurent ^i,j   De Truchis, Pierre ^k   Duval, Xavier ^l   Duvivier, Claudine ^m,n   Enel, Patricia ^o   Gasnault, Jacques ^p   Gaud, Catherine ^q   Gilquin, Jacques ^c   Guiguet, Marguerite ^a,b   Katlama, Christine ^r   Khuong Josses, Marie Aude ^c   Lacombe, Jean Marc ^a,b   Lang, Sylvie ^a,b   Lascaux, Anne Sophie ^s   Launay, Odile ^d,t   Mahamat, Aba ^u   Matheron, Sophie ^d,l   Meynard, Jean Luc ^v   Pavie, Juliette ^w   Pilorgé, Fabrice ^x   Piroth, Lionel ^y   Poizot Martin, Isabelle ^z   Potard, Valérie ^a,b   Pradier, Christian ^aa   Reynes, Jacques ^ab   Rouveix, Elisabeth ^ac   Selinger Leneman, Hana ^a,b   Simon, Anne ^r   Tattevin, Pierre ^ad   Tissot Dupont, Hervé ^o   Viard, Jean Paul ^c,d   Viget, Nathalie ^ae   Costagliola, Dominique ^a,b   more..

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e AVICENNE HOSPITAL   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

ⁱ CROIX ROUSSE HOSPITAL   (France)

^j CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^k RAYMOND POINCARÉ HOSPITAL   (France)

^l BICHAT HOSPITAL   (France)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ INSTITUT PASTEUR   (France)

^o HÔPITAL DE LA CONCEPTION   (France)

^p BICÊTRE HOSPITAL   (France)

^q CHU de Bellepierre Service d'Immunologie Clinique   (France)

^r PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^s HENRI MONDOR HOSPITAL   (France)

^t Institut Cochin   (France)

^u CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^v Section of Radiology   (France)

^w HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^x Inter Associative Groupe TRT 5   (France)

^y HÔPITAL DU BOCAGE   (France)

^z AIX MARSEILLE UNIVERSITY   (France)

^aa CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^ab GUI DE CHAULIAC HOSPITAL   (France)

^ac HÔPITAL AMBROISE PARÉ   (France)

^ad RENNES UNIVERSITY HOSPITAL   (France)

^ae CENTRE HOSPITALIER DE TOURCOING   (France)

more..

Author keywords

AIDS; Antiretroviral treatment; Cohort; Comorbidities; FHDH; HIV

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DATABASE; HUMAN IMMUNODEFICIENCY VIRUS;

ALCOHOL CONSUMPTION; ARTICLE; DEMOGRAPHY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OUTPATIENT; TOBACCO USE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COHORT ANALYSIS; COMPLICATION; FACTUAL DATABASE; FEMALE; FRANCE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HOSPITAL; MALE; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; DATABASES, FACTUAL; FEMALE; FRANCE; HEPATITIS; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84899654256     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyu002     Document Type: Article

References (49)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355:1158-59.
3. Lert F, Obadia Y, VESPA study team. Comment vit-on en France avec le VIH/sida? [How one lives in France with HIV/AIDS?] Population et Sociétés 2004;406:1-4.
4. Spaccaferri G, Cazein F, Lièvre L et al. Estimation de l'exhaustivité de la surveillance des cas de sida par la méthode capture-recapture, France, 2004-2006 [Estimation of completeness of AIDS surveillance with capture-recapture method]. BEH 2010;30:313-16.
5. Yéni P. Prise en Charge Médicale des Personnes Infectées par le VIH. Rapport 2006 [French guidelines for medical management of HIV-infected people. Report 2006]. Recommandations du Groupe d'Experts. Paris: La Documentation Française, 2006.
6. Yéni P. Prise en Charge Médicale des Personnes Infectées par le VIH. Rapport 2008 [French guidelines for medical management of HIV-infected people. Report 2008]. Recommandations du Groupe d'Experts. Paris: La Documentation Française, 2008.
7. Yéni P. Prise en Charge Médicale des Personnes Infectées par le VIH. Rapport 2010 [French guidelines for medical management of HIV-infected people. Report 2010]. Recommandations du Groupe d'Experts. Paris: La Documentation Française, 2010.
8. Vallier N, Salanave B, Weill A. Coût de Trente Affections de Longue Durée Pour l'Assurance Maladie [Cost of thirty longterm illness for the health insurance]. Points de repère no. 3. October 2006. Cnamts, Paris.
9. Thirion X, Sambuc R, San Marco JL. L'anonymat dans les enquêtes épidémiologiques: étude et mise en oeuvre d'une nouvelle méthode [Epidemiology and anonymity: a new method]. Rev Epidém et Santé Publ 1988;36:36-42.
10. Hessamfar-Bonarek M, Morlat P, Salmon D et al. Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19). Int J Epidemiol 2010;39:135-46.
11. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Lewden C, Bouteloup V, De Wit S et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41:433-45.
12. Lanoy E, Lewden C, Lièvre L et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV. Mortalité 2000 survey and death certificates. HIV Med 2009;10:236-45.
13. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th revision. Geneva: World Health Organization, 1993.
14. Writing committee for the Antiretroviral Cohort Collaboration. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol 2014;43:691-702.
15. Antiretroviral Therapy Cohort Collaboration (ART-CC). Mocroft A, Sterne JAC, Egger M et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009;48:1138-51.
16. Guiguet M, Mary M, Costagliola D et al. Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. AIDS 1992;6: 1405-06.
17. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999;13:2075-82.
18. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000;133:401-10.
19. Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group. Costagliola D, Ledergerber B, Torti C et al. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012;12:119-27.
20. Herida M, Mary-Krause M, Kaphan R et al. Incidence of non- AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
21. Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44.
22. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-59.
23. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001561.pdf (4 April 2013, date last accessed).
24. Piketty C, Selinger-Leneman H, Grabar S et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with cART. AIDS 2008;22:1203-11.
25. Piketty C, Selinger-Leneman H, Bouvier AM et al. The incidence of HIV-related anal cancer remains elevated despite long-term cART: Results from the French Hospital Database on HIV (FHDH-ANRS CO4 cohort). J Clin Oncol 2012;30:4360-66.
26. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
27. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958.
28. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351: 1959.
29. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-59.
30. Laurence J. Vascular complications associated with use of HIV protease inhibitors. [Letter] Lancet 1998;351:1960.
31. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-86.
32. Sabin CA, Worm S, Weber R et al. Recent Use of Abacavir and Didanosine, but not of Thymidine Analogues, Is Associated With Risk of Myocardial Infarction. Fifteenth Conference on Retrovirus and Opportunistic Infections, Boston, MA, 2008.
33. Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in HIV-infected patients: a case-control study nested within the FHDH ANRS Cohort CO4. Arch Intern Med 2010;170:1228-38.
34. Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010;24:1228-30.
35. Lang S, Mary-Krause M, Simon A et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012;55:600-07.
36. Lanoy E, Mary-Krause M, Tattevin P et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007;12:89-96.
37. Yazdanpanah Y, Sloan CE, Charlois-Ou C et al. Routine HIV screening in France: clinical impact and cost effectiveness. PLoS One 2010;5:e13132.
38. Grabar S, Kousignian I, Sobel A et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004;18:2029-38.
39. Fardet L, Mary-Krause M, Heard I, Partisani ML, Costagliola D. For the French Hospital Database on HIV. Influence of gender and HIV transmission group on initial HAART prescription and treatment response. HIV Med 2006;7:520-29.
40. Department of Health and Human Services. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. (4 April 2013, date last accessed).
41. Potard V, Weiss L, Lamontagne F et al. Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. J Acquir Immune Defic Syndr 2009;52:422-46.
42. Sàez-Cirión A, Bacchus C, Hocqueloux L et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI Study. PloS Pathog 2013;9:e1003211.
43. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009;23:1163-69.
44. Lanoy E, May M, Mocroft A et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009;23:2199-208.
45. Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res 2009;18:27-52.
46. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of18 HIV cohort studies. Lancet 2009;373:1352-63.
47. Cain LE, Logan R, Robins JM et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011;154:509-15.
48. Golub RM, Fontanarosa PB. Comparative effectiveness research: relative successes. JAMA 2012;307:1643-45.
49. Lewden C, Jougla E, Alioum A et al. Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. Epidemiol Infect 2006;134: 1345-52.